Oncolytics Biotech (TSE:ONC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Oncolytics Biotech reported positive results for its pelareorep and paclitaxel combination, showing significant improvements in survival rates for metastatic breast cancer patients. The company, with a solid cash position, plans to advance to a registration-enabling study. Oncolytics’ financial stability and promising clinical data suggest potential growth in the oncology sector.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
